title: Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers.
abstract: A series of phase I clinical studies were conducted to evaluate the safety of plasmid DNA and modified vaccinia virus Ankara malaria vaccines. The vaccines each encoded a polyepitope string fused to whole Plasmodium falciparum TRAP antigen. Forty-three healthy adult volunteers received the vaccines alone or in DNA/MVA prime-boost combinations. The DNA vaccine was administered either intramuscularly by needle or intradermally by a needleless delivery device. The MVA vaccine was administered intradermally by needle. The vaccines were well-tolerated by all three routes and in various DNA/MVA immunisation regimes. There were no severe or serious adverse events.
authors.affiliation: Nuffield Department of Medicine, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DU, UK. vasee.moorthy@ndm.ox.ac.uk
authors.forename: V S
authors.initials: VS
authors.lastname: Moorthy
authors.forename: S
authors.initials: S
authors.lastname: McConkey
authors.forename: M
authors.initials: M
authors.lastname: Roberts
authors.forename: P
authors.initials: P
authors.lastname: Gothard
authors.forename: N
authors.initials: N
authors.lastname: Arulanantham
authors.forename: P
authors.initials: P
authors.lastname: Degano
authors.forename: J
authors.initials: J
authors.lastname: Schneider
authors.forename: C
authors.initials: C
authors.lastname: Hannan
authors.forename: M
authors.initials: M
authors.lastname: Roy
authors.forename: S C
authors.initials: SC
authors.lastname: Gilbert
authors.forename: T E A
authors.initials: TE
authors.lastname: Peto
authors.forename: A V S
authors.initials: AV
authors.lastname: Hill
mesh_terms: D000328:Adult; D000595:Amino Acid Sequence; D000953:Antigens, Protozoan / Q000235:genetics / Q000276:immunology; D030161:Avian Proteins / Q000235:genetics / Q000276:immunology; D000939:Epitopes / Q000737:chemistry / Q000276:immunology; D005136:Eye Proteins / Q000235:genetics / Q000276:immunology; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D008099:Liver / Q000469:parasitology*; D017780:Malaria Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000592:standards*; D016778:Malaria, Falciparum / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D010957:Plasmids / Q000276:immunology; D011537:Pruritus / Q000139:chemically induced; D012449:Safety; D019444:Vaccines, DNA / Q000008:administration & dosage / Q000592:standards*; D014616:Vaccinia virus / Q000276:immunology*; D014765:Viral Vaccines / Q000009:adverse effects / Q000276:immunology* / Q000592:standards
chemical_list: D000953:Antigens, Protozoan; D030161:Avian Proteins; D000939:Epitopes; D005136:Eye Proteins; D017780:Malaria Vaccines; D019444:Vaccines, DNA; D014765:Viral Vaccines